

February 2006 Edition

A Pocket Guide to Adult HIV/AIDS Treatment:

Companion to
**A Guide to Primary Care of
People with HIV/AIDS**

John G. Bartlett, MD
Professor of Medicine
Chief, Division of Infectious Diseases
Director, AIDS Service
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Acknowledgements

Richard W. Dunning, MS, MHS, edited the August 2004 edition.
Helen Schietinger, MA, ACRN, edited subsequent updates.
Paul Pham, Pharm D, reviewed the manuscript. Cover artwork was
created by Laura Spofford. Design and layout was done by
Patrice Lincoln and Jim Concannon.

Department of Health and Human Services
Health Resources and Services Administration
HIV/AIDS Bureau
Parklawn Building, Room 7-05
5600 Fishers Lane
Rockville MD 20857
<http://www.hab.hrsa.gov>

Publication date February, 2006

Table of Contents

References	v
Important Information for Users of This Pocket Guide	vi
List of Abbreviations Used in This Pocket Guide	1
Drug Information	
Drug Table 1. Antiretroviral Agent Characteristics	2
Drug Table 2. Antiretroviral Agents, Class Adverse Reactions	8
Drug Table 3. Antiretroviral Agents, Adverse Reactions: “Black Box” Warnings	11
Drug Table 4. Combination Antiretroviral Therapy, Dose Adjustments	12
Drug Table 5. Drug Interactions: Contraindicated Combinations	13
Drug Table 6. Drug Interactions: Nucleosides	14
Drug Table 7. Drug Interactions: Combinations with PIs or NNRTIs Requiring Dose Modifications	15
Antiretroviral Therapy	
Adult ART Table 1. When to Start Therapy	17
Adult ART Table 2. Suggested Minimum Target Trough Levels	17
Adult ART Table 3. Starting Regimens for Antiretroviral Naïve Patients	18
Adult ART Table 4. Advantages and Disadvantages of Antiretroviral Regimens	19
Adult ART Table 5. Antiretroviral Regimens or Components That Are Not Generally Recommended	20
Adult ART Table 6. Laboratory Monitoring	22
Adult ART Table 7. Resistance Mutations	23
Therapeutic Failure	25
Adult ART Table 8. Methods to Achieve Readiness to Start HAART & Maintain Adherence	27
Adult ART Table 9. National Cholesterol Education Program: Indications for Dietary or Drug Therapy for Hyperlipidemia	28
Adult ART Table 10. Drug Therapy for Hyperlipidemia	29

Pregnancy and HIV

Antiretroviral Therapy in Pregnancy	30
Pregnancy Table 1. Preferred Antiretroviral Agents	30
Pregnancy Table 2. Antiretroviral Agents: Pharmacokinetic and Toxicity Data	31
Pregnancy Table 3. Antiretroviral Drugs for Delivery	32
Pregnancy Table 4. Pregnancy Issues	33
Pregnancy Table 5. Clinical Scenarios and Management of Untreated Pregnant Patients Including C-Section	33
Pregnancy Table 6. Clinical Scenarios and Management of Treated Pregnant Patients Including C-Section	34
Pregnancy Table 7. Delivery Procedures and Therapy	34

Prevention of HIV for Providers in Three Steps

Step 1: Screen Patients for Risk Behaviors	35
Step 2: Behavioral Interventions	36
Step 3: Partner Counseling and Notification	37

Opportunistic Infections

Adult OI Table 1. 2001 USPHS/IDSA Guidelines for Prevention of Opportunistic Infections	38
Tuberculosis and HIV	42
Adult OI Table 2. Recommended Drug Regimens for Treatment of Latent TB in HIV Co-infected Adults	43
Adult OI Table 3. Monitoring of Patients on Latent TB Prophylaxis	44
Special Considerations for TB Treatment with HIV Co-infection	45
Adult OI Table 4. Treatment of Drug-Susceptible TB	46
Adult OI Table 5. Doses of Antituberculosis Drugs – First-line Drugs	47
Adult OI Table 6. Management of Opportunistic Infections	48

Occupational HIV Postexposure Prophylaxis (PEP)

Considerations in Occupational Exposure to HIV	52
Occupational Postexposure Table 1. Exposure Contingencies	53
Occupational Postexposure Table 2. Indications for HIV PEP	54
Management of Health Care Workers (HCWs) With Potential HIV Exposure	55
Occupational Postexposure Table 3. Recommended Regimens	57
Resources for Consultation	57

References: A Pocket Guide to Adult HIV/AIDS Treatment:

- The (DHHS) Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. (The Living Document: October, 6 2005). Available at <http://www.aidsinfo.nih.gov/guidelines>.
- 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. November 28, 2001. Available at <http://www.aidsinfo.nih.gov>.
- USPHS/IDSA. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents. *MMWR Recommendations and Reports* 53 (RR15):1-112, December 17, 2004. Available at <http://www.aidsinfo.nih.gov>.
- Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. June 23, 2005. Available at <http://www.aidsinfo.nih.gov>.
- ATS/CDC Statement on Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. The *MMWR Recommendations and Reports* Vol. 49, No. RR-6, June 9, 2000. Available at <http://www.cdc.gov/nchstp/tb>.
- Incorporating HIV Prevention into the Medical Care of Persons Living with HIV: Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. *MMWR Recommendations and Reports* Vol. 52, No. RR-12, July 18, 2003. Available at <http://www.aidsinfo.nih.gov>.
- Integrating Nutrition Therapy into Medical Management of Human Immunodeficiency Virus. *Clin Infect Dis* 2003; 36; Suppl 2:S51-109.
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis, *Am J Respir Crit Care Med* 2003;167(4):603. Available at <http://www.aidsinfo.nih.gov>.
- Updated US Public Health Service Guidelines for the Management of Occupational Exposures to HIV and recommendations for Postexposure Prophylaxis. *MMWR* 2005;54:RR-9. Available at <http://www.aidsinfo.nih.gov>.
- Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States: Recommendations from the U.S. Department of Health and Human Services. *MMWR* 2005;54:RR-2. Available at <http://www.aidsinfo.nih.gov>.

Important Information for Users of This Pocket Guide

This document is provided as an information resource for physicians and other health care professionals to guide them in the appropriate treatment of patients with HIV/AIDS. Recommendations for care and treatment change rapidly, and opinions can be controversial; therefore, physicians and other health care professionals are encouraged to consult other sources, especially manufacturers' package inserts, and confirm the information contained in these tables. The individual physician or other health care professional should use his/her best medical judgment in determining appropriate patient care or treatment because no single reference or service can take the place of medical training, education, and experience. Although these tables have been carefully prepared and reviewed, the author makes no warranty as to the reliability, accuracy, timeliness, usefulness, or completeness of the information. The data presented herein are for informational purposes only. Determination of appropriate treatment is the responsibility of the treating physician.

Abbreviations Used in This Pocket Guide

Drug Abbreviations

ABC: abacavir (<i>Ziagen</i>)	IVIG: intravenous immune globulin
APV: amprenavir (<i>Agenerase</i>)	LPV/r: lopinavir/ritonavir (<i>Kaletra</i>)
ATV: atazanavir (<i>Reyataz</i>)	NFV: nelfinavir (<i>Viracept</i>)
AZT: zidovudine (<i>Retrovir</i>)	NNRTI: non-nucleoside reverse transcriptase inhibitor
CBV: Combivir (AZT+3TC)	NRTI: nucleoside reverse transcriptase inhibitor
ddI: didanosine (<i>Videx</i>)	NVP: nevirapine (<i>Viramune</i>)
d4T: stavudine (<i>Zerit</i>)	PI: protease inhibitor
ddC: zalcitabine (<i>Hivid</i>)	RBT: rifabutin (<i>Mycobutin</i>)
DLV: delavirdine (<i>Rescriptor</i>)	RTV: ritonavir (<i>Norvir</i>)
EFV: efavirenz (<i>Sustiva</i>)	r: ritonavir in dose <400 mg/day
ENF: enfuvirtide (<i>Fuzeon, T-20</i>)	SQV: saquinavir (<i>Invirase, Fortovase</i>)
FTC: emtricitabine (<i>Emtriva</i>)	TPV: tipranavir (<i>Artivus</i>)
FTV: Fortovase (<i>saquinavir</i> , soft gel cap)	3TC: lamivudine (<i>Epivir</i>)
FPV: fosamprenavir (<i>Lexiva</i>)	T-20: enfuvirtide (<i>Fuzeon</i>)
HU: hydroxyurea	TDF: tenofovir (<i>Virad</i>)
IDV: indinavir (<i>Crixivan</i>)	TMP-SMX: trimethoprim sulfamethoxazole
INH: isoniazid	TZV: <i>Trizivir</i> (ABC+AZT+3TC)
INV: Invirase (<i>saquinavir</i> , hard gel cap)	VZIG: varicella zoster immune globulin
	ZDV: zidovudine (<i>Retrovir</i>)

Miscellaneous Abbreviations

ART: antiretroviral therapy	q: every
EC: enteric coated	qd: daily
HAART: highly active antiretroviral therapy	qid: four times per day
IV: intravenous	qm: monthly
IM: intramuscular	qod: every other day
VL: viral load	qw: every week
bid: twice per day	soln: solution
biw: twice per week	tid: three times per day
CNS: central nervous system	tiw: three times per week
hs: bedtime (hour of sleep)	TAMS: thymidine analogue assoc. mutations
mo: month	ULN: upper limit of normal
po: by mouth	